Two young Indian lawyers today bagged the prestigious Antitrust Writing Award for their article on "compulsary licensing in India".

BDR Pharma has filed an application with the Mumbai Patent Office, seeking compulsory licence to market a crucial cancer drug, dasatinib

Out of the total analyst recommendations, 5 are buy and one is a sell. The average target price is Rs 530 - 22% more from the current marke...

The Indian patents appeals board had last year dismissed Bayer’s petition seeking a stay on the “compulsory licence” issued to Natco.

Bayer today said it will continue to defend its IP rights while expressing disappointment at the IPAB decision to reject the firm's plea to...

A panel set up to look into the pricing mechanism for patented drugs has said that prices have to be decided after deliberations with manuf...

The department is the convener of an inter-ministerial group comprising DIPP and the Health Ministry to modulate a pricing mechanism for pa...

The government had defended the move, with Commerce and Industry Minister Anand Sharma stating that India did not violate any WTO norms.

In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original medicine's pr...

The government has clarified that no applications are pending from pharmaceutical companies seeking compulsory licences for producing low-c...

Amid concerns that more domestic pharma companies could seek compulsory licenses to replicate patented drugs, the government said no such a...

We have mostly targeted unaffordable life saving drugs which are either unavailable or in-adequately available at an exorbitant cost. These...

The decision to allow Natco Pharma to sell Bayer's patented cancer drug Nexavar has divided the pharmaceutical industry.

Shares of Natco Pharma extended gains for the second straight day on Tuesday after the company reported that it had received a license for ...

Natco Pharma has applied for the country's first compulsory licence to sell a generic version of Bayer's patented medicine.

Several global drugmakers, including Pfizer, Roche and Bayer, have not met full mandatory disclosures of their patented medicines in India,...

Natco Pharma plans to seek a compulsory licence to make Bayer AG's Nexavar in India, invoking a provision in local laws that allows generic...